stockportfolio.pro
CRL vs PODD: Which Stock Is the Better Buy?
Charles River Laboratories International, Inc. and Insulet Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — CRL vs PODD, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Charles River Laboratories International, Inc. (CRL) | Insulet Corporation (PODD) | |
|---|---|---|
| Market cap | $11.1B | $11.4B |
| Revenue (latest FY) | $4.02B | $2.71B |
| Net income (latest FY) | $-144.34M | $247.10M |
| Revenue growth (5y CAGR) | 6.5% | 24.5% |
| Net margin | -3.6% | 9.1% |
| Return on equity | -4.6% | 16.3% |
| P/E ratio | — | 38.4 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 9 | 8 |
| Positive free cash flow | Yes | Yes |
See the full CRL vs PODD breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open CRL's full financials → Open PODD's full financials →More comparisons
Frequently asked questions
Which is bigger, CRL or PODD?
Insulet Corporation is larger by market capitalization — $11.4B versus $11.1B.
Which grows faster, CRL or PODD?
Over the last five fiscal years, Insulet Corporation grew revenue faster — 24.5%/yr versus 6.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.